Shares of Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $7.86.
A number of research firms have recently weighed in on PRME. Wall Street Zen upgraded shares of Prime Medicine from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Citigroup restated a “market outperform” rating on shares of Prime Medicine in a research report on Friday, September 25th. Jefferies Financial Group reaffirmed a “market outperform” rating on shares of Prime Medicine in a report on Monday, September 28th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Prime Medicine in a research report on Friday, September 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a research note on Monday, August 31st.
Check Out Our Latest Analysis on PRME
Prime Medicine Stock Performance
Prime Medicine stock opened at $4.27 on Wednesday. The firm has a 50 day moving average of $3.70 and a 200 day moving average of $3.51. The firm has a market capitalization of $774.49 million, a price-to-earnings ratio of -4.45 and a beta of 2.13. Prime Medicine has a 12-month low of $2.67 and a 12-month high of $5.91.
Prime Medicine (NASDAQ:PRME – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Prime Medicine had a negative return on equity of 222.88% and a negative net margin of 2,497.56%. The business had revenue of $4.21 million for the quarter. On average, analysts predict that Prime Medicine will post -0.97 EPS for the current year.
Prime Medicine News Summary
Investors following PRME have been watching these news items:
- Positive Sentiment: Third-quarter revenue was about $4.2 million, above the cited FactSet estimate of $1.3 million. The loss of $0.22 per share was also narrower than the $0.23 consensus estimate and improved from a $0.32 loss a year earlier. Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Positive Sentiment: Prime Medicine closed a public offering that brought in approximately $143.7 million in gross proceeds. The added capital could help fund development of its Prime Editing programs across liver, lung, immunology and oncology. Prime Medicine Announces Closing of Public Offering
- Negative Sentiment: The offering involved 41.1 million new shares sold at $3.50 each, diluting existing shareholders and potentially creating near-term selling pressure. Offering details
Institutional Trading of Prime Medicine
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Prime Medicine in the third quarter worth approximately $28,000. Royal Bank of Canada increased its holdings in Prime Medicine by 89.3% during the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock worth $32,000 after purchasing an additional 4,365 shares during the period. Wealthfront Advisers LLC bought a new stake in Prime Medicine during the 1st quarter valued at $36,000. Kingsview Wealth Management LLC bought a new stake in Prime Medicine during the 2nd quarter valued at $37,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Prime Medicine in the 1st quarter worth $41,000. 70.37% of the stock is owned by hedge funds and other institutional investors.
Prime Medicine Company Profile
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
Featured Stories
- Five stocks we like better than Prime Medicine
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
